Ontology highlight
ABSTRACT:
SUBMITTER: Chowdhury S
PROVIDER: S-EPMC4167832 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
Chowdhury Simon S Matrana Marc R MR Tsang Christopher C Atkinson Bradley B Choueiri Toni K TK Tannir Nizar M NM
Hematology/oncology clinics of North America 20110801 4
Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in pati ...[more]